Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single-Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands

Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand

(2013) Lei Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

New avenues for anti-epileptic drug discovery and development

(2013) Wolfgang Löscher et al.   NATURE REVIEWS DRUG DISCOVERY

Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H

(2013) Florian Bretin et al.   EJNMMI Research

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial

(2012) Wim Van Paesschen et al.   EPILEPSIA

PET radiotracers: crossing the blood–brain barrier and surviving metabolism

(2009) Victor W. Pike   TRENDS IN PHARMACOLOGICAL SCIENCES

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development

(2008) Dean F Wong et al.   NEUROPSYCHOPHARMACOLOGY